share_log

HC Wainwright & Co. Reiterates Buy on Inozyme Pharma, Maintains $16 Price Target

Benzinga ·  Aug 8, 2023 12:24

HC Wainwright & Co. analyst Edward White reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $16 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment